Literature DB >> 19841143

Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.

V Nagappan1, D Boikov, J A Vazquez.   

Abstract

Echinocandins have become the drug of choice in infections caused by Candida glabrata. The objective of this study was to evaluate the in vitro activity of caspofungin alone and in combination against C. glabrata. In vitro assays demonstrated that caspofungin alone showed excellent fungicidal activity against C. glabrata, including fluconazole-resistant strains. The combination of caspofungin and azole antifungals showed potential synergy against C. glabrata. Overall, caspofungin demonstrated excellent in vitro activity, alone and in combination, against strains of C. glabrata.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19841143      PMCID： PMC2798515          DOI： 10.1128/AAC.01339-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 2.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 4.  Current therapy of pulmonary and disseminated fungal diseases.

Authors:  A M Stamm; W E Dismukes
Journal:  Chest       Date:  1983-06       Impact factor: 9.410

5.  Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains.

Authors:  S Maesaki; P Marichal; M A Hossain; D Sanglard; H Vanden Bossche; S Kohno
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

6.  Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.

Authors:  H Wisplinghoff; H Seifert; R P Wenzel; M B Edmond
Journal:  Clin Microbiol Infect       Date:  2006-02       Impact factor: 8.067

7.  Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.

Authors:  Alvaro Villanueva; Eduardo Gotuzzo; Eduardo G Arathoon; L Miguel Noriega; Nicholas A Kartsonis; Robert J Lupinacci; Juanita M Smietana; Mark J DiNubile; Carole A Sable
Journal:  Am J Med       Date:  2002-09       Impact factor: 4.965

9.  Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus.

Authors:  C Bartizal; F C Odds
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus.

Authors:  Eric Dannaoui; Olivier Lortholary; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
View more
  2 in total

1.  Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.

Authors:  Elisabetta Spreghini; Fiorenza Orlando; Maurizio Sanguinetti; Brunella Posteraro; Daniele Giannini; Esther Manso; Francesco Barchiesi
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

2.  In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran.

Authors:  Hamideh Shekari Ebrahim Abad; Farideh Zaini; Parivash Kordbacheh; Mahmoud Mahmoudi; Mahin Safara; Vida Mortezaee
Journal:  Jundishapur J Microbiol       Date:  2015-06-27       Impact factor: 0.747
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.